{
    "clinical_study": {
        "@rank": "43634", 
        "acronym": "ALIBIRDII", 
        "arm_group": [
            {
                "arm_group_label": "Functional bioactive supplement", 
                "arm_group_type": "Active Comparator", 
                "description": "The functional bioactive supplement is composed of antioxidant extracted from rosemary, oligosaccharides derived from lactulose and bioactive peptides. It will be used for obese and overweight treatment"
            }, 
            {
                "arm_group_label": "Maltodextrin and saccharose", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The control supplement is composed of maltodextrin and saccharose . It has no effect for obese and overweight treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose this study is to evaluate the therapeutic effect of a functional bioactive\n      supplement associated with a hypocaloric equilibrated diet to treat obese and overweight\n      individuals. The functional bioactive supplement, containing antioxidant extracted from\n      rosemary, oligosaccharides derived from lactulose and bioactive peptides, was developed to\n      satiety control, improves of anti-inflammatory response and antioxidant defense mechanisms\n      as well as to weight loss."
        }, 
        "brief_title": "Functional Bioactive Supplement Effect in Lost Weight Treatment", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity and Overweight", 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Overweight"
            ]
        }, 
        "detailed_description": {
            "textblock": "A randomized, parallel, double-blind, controlled was performed to evaluate the therapeutic\n      effect of a functional bioactive supplement associated with a hypocaloric equilibrated diet\n      to treatment of obesity and overweight.\n\n      Women aged between 18 and 65 years with obesity and overweight diagnosis (IMC >25<35 kg/m2)\n      were included in the study. The clinical trial will be performed in the Clinical Nutrition\n      Department of La Paz University Hospital, in Madrid.  All of the volunteers will receive a\n      dietetic treatment with 1500 Kcal/day and physical activity recommendations during the\n      study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women from 45 to 75 years old;\n\n          -  Overweight (IMC \u226525<30 Kg/m2) or obese (IMC \u226530<35 Kg/m2) volunteers\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Subjects with drug consumption (lipid-lowering, oral hypoglycemic agents and / or\n             hypertensive) in less than one month period;\n\n          -  Subjects with Diabetes Mellitus insulin dependent;\n\n          -  Individuals that stop smoking in the next 12 weeks (during the study);\n\n          -  Subjects with increased alcohol consumption (> 1 glass of vine);\n\n          -  Subjects that consume drugs, vitamins, minerals, prebiotics or/and probiotics that\n             interfere with the body's response to the extracts in the 2 weeks before to baseline;\n\n          -  Subjects with drugs consumption special diet due to disease as celiac disease,\n             chronic renal failure, etc;\n\n          -  Subjects with disorders associated with eating behaviour;\n\n          -  Subjects with drugs or supplements consumption to weight lost;\n\n          -  Subjects with physical problems complying with the recommendations of physical\n             activity and diet indicated;\n\n          -  Subjects who refuse to perform the indicated dietary changes throughout the study;\n\n          -  Subjects with diseases that could be involucrate in weight lost (not controlled\n             hypothyroidism, serious psychiatric illness, etc.);\n\n          -  Subjects with mental disease or low cognitive function;\n\n          -  Subjects with severe diseases (hepatic, kidney, cancer\u2026);\n\n          -  Pregnant women or lactating;\n\n          -  Subjects with physical problems complying with the recommendations of physical\n             activity.\n\n          -  Subjects with intensive physical activity;"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "109", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024425", 
            "org_study_id": "ALIBIRDII"
        }, 
        "intervention": [
            {
                "arm_group_label": "Functional bioactive supplement", 
                "intervention_name": "Functional bioactive supplement", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Maltodextrin and saccharose", 
                "intervention_name": "Control supplement", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Clinical trials", 
            "Adult", 
            "Women", 
            "Functional food", 
            "Dietary Supplements", 
            "Overweight", 
            "Obese", 
            "Absorptiometry, Dual X-Ray", 
            "Rosmarinus", 
            "Oligosaccharides", 
            "Lactulose", 
            "Bioactive peptide"
        ], 
        "lastchanged_date": "December 27, 2013", 
        "link": [
            {
                "description": "Institute for Health Research IdiPAZ", 
                "url": "http://www.idipaz.es"
            }, 
            {
                "description": "Research group in Nutrition and Functional Foods (NUTRINVEST)", 
                "url": "http://www.nutrinvest.com"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28061"
                }, 
                "name": "Hospital Universitario La Paz"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind Trial to Evaluate the Effect of a Functional Bioactive Supplement Associated With a Hypocaloric Equilibrated Diet to Treatment of Obese and Overweight Individuals", 
        "other_outcome": [
            {
                "measure": "Appetite and satiety", 
                "safety_issue": "No", 
                "time_frame": "0 , 3, 6, 9 and 12 weeks"
            }, 
            {
                "description": "Frequent daily evacuations, format and consistency of the feces, total and segmental transit time. The format and consistency of the feces was evaluated in accordance with the Bristol Stool Form Scale (stool are rated based on water content of the feces, with 1 meaning hard stools to 7 meaning liquid stools)", 
                "measure": "Frequent daily evacuations", 
                "safety_issue": "No", 
                "time_frame": "4 Weeks"
            }, 
            {
                "description": "Adherence and Tolerance Parameters: adherence and tolerance to the products and diet prescribed", 
                "measure": "Adherence and Tolerance Parameters", 
                "safety_issue": "No", 
                "time_frame": "0 , 3, 6, 9 and 12 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "Hospital Universitario La Paz", 
            "last_name": "Carmen Gomez Candela, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Clinical response - changes in body composition:  weight, waist circumference and Absorptiometry, Dual X-Ray.The primary outcome result measurement was the lost weight, changes in body composition", 
            "measure": "Changes in body composition", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024425"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Life style and health status: Life style and physical activity  questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and Week 12"
            }, 
            {
                "measure": "Genetic analysis", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and Week 12"
            }, 
            {
                "measure": "Metabolomic analyses", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and Week 12"
            }, 
            {
                "description": "Endothelial function markers: eNOS, VCAM-1, PAI1 and blood pressure", 
                "measure": "Endothelial function markers", 
                "safety_issue": "No", 
                "time_frame": "Week 0 y Week 12"
            }, 
            {
                "description": "Satiety hormones: ghrelin, GLP-1; Leptin; adiponectin and NPY", 
                "measure": "Satiety hormones", 
                "safety_issue": "No", 
                "time_frame": "Week 0 y Week 12"
            }, 
            {
                "description": "Inflammatory markers: TNF-\u03b1, IL-6, PCR and fibrinogen", 
                "measure": "Inflammatory markers", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and Week 12"
            }, 
            {
                "description": "Glucose Metabolism: glucose, basal insulin, HbA1c (in diabetic patients), HOMA index (glycemic insulin sensitivity index was calculated using the formula: HOMA-IR = fasting glucose (mmol/l)/fasting immunoreactive insulin (mU/ml)/22\u20225)", 
                "measure": "Glucose Metabolism", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and Week 12"
            }, 
            {
                "description": "Lipid profile: Cholesterol, LDL-Cholesterol, HDL-Cholesterol, Triglycerides", 
                "measure": "Lipid profile: Cholesterol", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and Week 12"
            }, 
            {
                "description": "Oxidative Stress Parameters: plasma antioxidant capacity (FRAP, ferric reducing antioxidant power) and lipidic peroxidation (TBARS, thiobarbituric acid reactive substances assay), oxidized LDL, PON1, F2-isoprostanes", 
                "measure": "Oxidative Stress Parameters", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and Week 12"
            }, 
            {
                "description": "Adverse effects: transaminases and creatinine", 
                "measure": "Adverse effects", 
                "safety_issue": "Yes", 
                "time_frame": "0 , 3, 6, 9 and 12 weeks"
            }
        ], 
        "source": "Instituto de Investigaci\u00f3n Hospital Universitario La Paz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto de Investigaci\u00f3n Hospital Universitario La Paz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}